Shuiying Hu holds a B.S. from Shanxi University, an M.S. from the Chinese Academy of Agricultural Sciences, and a Ph.D. in Pharmaceutical Sciences from West Virginia University in 1995, 1999, and 2004, respectively. She is now an Associate Professor at the Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University. Before joining OSU, she was a Postdoctoral Research Fellow at Johns Hopkins University (2004–2006) and St. Jude Children’s Research Hospital (2006–2011). Her research is to evaluate the contribution of uptake transporters, in particular the OATP1B-type transporters, in the disposition and toxicity of anticancer drugs, with particular emphasis on peripheral neurotoxicity. Her laboratory utilizes multi-level approaches including in vitro, and in vivo models, and aims to understand the underlying mechanisms that drive the extensive inter-individual pharmacokinetic variability, drug transporter regulation, antitumor efficacy, and drug-drug interaction in response to drug therapy in cancer patients. Another area of research interest is the design of preclinical and clinical studies to evaluate pharmaceutical agents as modulators of side effects associated with tubulin poisons, such as paclitaxel and vincristine.